trial

Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia

NCTId NCT02240173
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Unknown
Enrollment 100 (estimated)
Sponsored by Federal Neuro-Psychiatric Hospital, Yaba
Primary completion 2017-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Unknown
Enrollment
100 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2017-06
Primary completion
2017-12
Eligibility
ALL

Interventions & indications

Drugs
JobelynHaloperidol

Sponsors

Federal Neuro-Psychiatric Hospital, YabaLead Sponsor

Investigators

1
Moses Ojo, M.D.Principal Investigator

Sites

1 total
Lagos, Nigeria

Linked catalysts

1
Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophr — primary completion2017-12

Facts & assertions

4 sourced
Enrollment
100
Phase
PHASE1,PHASE2
Primary Completion Date
2017-12
Status
UNKNOWN
relationships
The graph out of here
drug
Jobelyn
drug
Haloperidol
drug
lead_sponsor
Federal Neuro-Psychiatric Hospital, Yaba
company
indication
Schizophrenia and Disorders With Psychotic Features
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
investigator
Moses Ojo, M.D.
person